Tumor Cell Density Model May Guide Intensified Neoadjuvant Chemoradiotherapy Use in Locally Advanced Rectal Cancer

Although the original ARISTOTLE trial showed limited benefit from irinotecan overall, the post hoc analysis suggested that tumor cell density may help identify a subgroup of patients with rectal cancer who derive meaningful benefit.